Open AccessThe effectiveness of mebicar in chronic coronary heart disease
Author(s) -
R. A. Kamburg,
D. A. Valimukhametova
Publication year - 1984
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kazmj89505
Subject(s) - medicine , coronary heart disease , bradycardia , pharmacotherapy , intensive care medicine , circulatory system , cardiology , heart disease , disease , chronic disease , coronary disease , heart rate , blood pressure
Modern pharmacotherapy of chronic coronary heart disease (HIBS) is based on the use of two main groups of drugs nitrates and beta-blockers. The effectiveness of other drugs in the complex treatment of this disease is being reviewed and constantly debated [1, 2]. The treatment of HIBS, combined with bradycardia, circulatory insufficiency, bronchospastic conditions, intolerance or contraindications to the use of nitrates and beta-blockers, is a great difficulty.